Rania A Tohme1, Lisa Bulkow, Chriss E Homan, Susan Negus, Brian J McMahon. 1. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: rtohme@cdc.gov.
Abstract
BACKGROUND: A high prevalence of reactivation of hepatitis B has been documented among immunosuppressed individuals in the inactive phase of chronic hepatitis B; However, the proportion of and the risk factors for reactivation are largely unknown among non-immunosuppressed persons. OBJECTIVES: Estimate the incidence rate of and risk factors for hepatitis B reactivation in a population-based cohort of persons in the inactive phase of chronic hepatitis B in Alaska. STUDY DESIGN: A cohort of 414 Alaska Native Persons in the inactive phase of hepatitis B (HBV DNA<2000 IU/mL and normal alanine aminotransferase (ALT) for 12 months) was followed-up for 10 years. Reactivation of hepatitis B was defined as HBV DNA≥2000 IU/mL and ALT≥40 IU/L. Cox-proportional hazards regression models were used to identify factors associated with reactivation. RESULTS: A total of 36 (9%) persons had reactivation during 2984 person-years of follow-up, with an annual incidence of 1.2%. Persons aged ≥50 years (1.8%) at study entry had the highest incidence rates of reactivation although incidence rates were not significantly different by age group. Risk factors for hepatitis B reactivation were male sex (Hazard Ratio (HR)=2.41; 95% Confidence Interval (CI): 1.17-4.96), HBV DNA≥1000 IU/mL at study entry (HR=7.61; 95% CI: 2.81-20.6), and HBV genotype B (HR=6.08; 95% CI: 1.32-28.0). CONCLUSIONS: The incidence of hepatitis B reactivation was low during the 10 years of follow-up. However, given the higher risk of reactivation than their counterparts, males, and those with HBV DNA≥1000 IU/mL need to be followed-up more frequently. Published by Elsevier B.V.
BACKGROUND: A high prevalence of reactivation of hepatitis B has been documented among immunosuppressed individuals in the inactive phase of chronic hepatitis B; However, the proportion of and the risk factors for reactivation are largely unknown among non-immunosuppressed persons. OBJECTIVES: Estimate the incidence rate of and risk factors for hepatitis B reactivation in a population-based cohort of persons in the inactive phase of chronic hepatitis B in Alaska. STUDY DESIGN: A cohort of 414 Alaska Native Persons in the inactive phase of hepatitis B (HBV DNA<2000 IU/mL and normal alanine aminotransferase (ALT) for 12 months) was followed-up for 10 years. Reactivation of hepatitis B was defined as HBV DNA≥2000 IU/mL and ALT≥40 IU/L. Cox-proportional hazards regression models were used to identify factors associated with reactivation. RESULTS: A total of 36 (9%) persons had reactivation during 2984 person-years of follow-up, with an annual incidence of 1.2%. Persons aged ≥50 years (1.8%) at study entry had the highest incidence rates of reactivation although incidence rates were not significantly different by age group. Risk factors for hepatitis B reactivation were male sex (Hazard Ratio (HR)=2.41; 95% Confidence Interval (CI): 1.17-4.96), HBV DNA≥1000 IU/mL at study entry (HR=7.61; 95% CI: 2.81-20.6), and HBV genotype B (HR=6.08; 95% CI: 1.32-28.0). CONCLUSIONS: The incidence of hepatitis B reactivation was low during the 10 years of follow-up. However, given the higher risk of reactivation than their counterparts, males, and those with HBV DNA≥1000 IU/mL need to be followed-up more frequently. Published by Elsevier B.V.
Entities:
Keywords:
AASLD; AFP; ALT; AST; American Association for the Study of Liver Disease; BMI; CI; DNA; HBV; HBeAg; HBsAg; HCC; HR; Hazard Ratio; Hepatitis B; Incidence; NIH; National Institutes of Health; PCR; Reactivation of infection; Risk factors; SD; alanine aminotransferase; alpha-fetoprotein; anti-HBc; anti-HBe; anti-HBs; antibody to hepatitis B core; antibody to hepatitis B surface antigen; antibody to hepatitis e antigen; aspartate aminotransferase; body mass index; confidence interval; deoxyribonucleic acid; hepatitis B e antigen; hepatitis B surface antigen; hepatitis B virus; hepatocellular carcinoma; polymerase chain reaction; standard deviation.
Authors: G H Zacharakis; J Koskinas; S Kotsiou; M Papoutselis; F Tzara; N Vafeiadis; A J Archimandritis; K Papoutselis Journal: J Med Virol Date: 2005-10 Impact factor: 2.327
Authors: Stephen E Livingston; Josephine P Simonetti; Brian J McMahon; Lisa R Bulkow; Kathy J Hurlburt; Chriss E Homan; Mary M Snowball; Henry H Cagle; James L Williams; Vladimir P Chulanov Journal: J Infect Dis Date: 2006-11-21 Impact factor: 5.226
Authors: B J McMahon; S Schoenberg; L Bulkow; R B Wainwright; M A Fitzgerald; A J Parkinson; E Coker; D Ritter Journal: Am J Epidemiol Date: 1993-10-01 Impact factor: 4.897
Authors: J P Villeneuve; M Desrochers; C Infante-Rivard; B Willems; G Raymond; M Bourcier; J Côté; G Richer Journal: Gastroenterology Date: 1994-04 Impact factor: 22.682
Authors: P P Gounder; L R Bulkow; M Snowball; S Negus; P R Spradling; B C Simons; B J McMahon Journal: Aliment Pharmacol Ther Date: 2016-04-08 Impact factor: 8.171
Authors: Norah A Terrault; Natalie H Bzowej; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; M Hassan Murad Journal: Hepatology Date: 2015-11-13 Impact factor: 17.425
Authors: Kali Zhou; Abdus S Wahed; Stewart Cooper; Adrian M Di Bisceglie; Robert J Fontana; Marc G Ghany; Mandana Khalili; Anna S Lok; Robert Perrillo; William M Lee; Daryl T Y Lau; Richard Sterling; Harry L A Janssen; Norah A Terrault Journal: Am J Gastroenterol Date: 2019-11 Impact factor: 10.864
Authors: Lei Wang; Min Cao; Qing Lu Wei; Zhong Hua Zhao; Qin Xiang; Hui Juan Wang; Hua Tang Zhang; Guo Qi Lai Journal: PLoS One Date: 2017-04-20 Impact factor: 3.240